Enhance Early Biomarker Discovery: Translating In Vitro and In Vivo Multi-Omics Oncology Data

Life Sciences, Pharmaceutical, Drug Discovery & Development, Biomarkers,
  • Thursday, January 16, 2025 | 11am EST (NA) / 4pm GMT (UK) / 5pm CET (EU-Central)
  • 60 min

Unlock the power of multi-omics data to revolutionize early biomarker discovery in oncology drug development.

In this webinar, the expert speaker will explore the critical role of early biomarker identification in de-risking drug candidates and increasing clinical success rates. As the landscape of preclinical oncology evolves, integrating comprehensive multi-omics analysis with advanced in vitro and in vivo screening models has become essential for generating translatable and actionable insights.

The speaker will delve into the intricate process of leveraging diverse oncology models from traditional cell lines to innovative organoids and patient-derived xenografts (PDX). She will provide valuable guidance on how these advanced patient models can yield deeper insights into precision medicine approaches, drug resistance mechanisms and effective combination therapies. By harnessing the complete potential of multi-omics data, researchers can make informed decisions that align treatments with patient responses.

Throughout the session, she will address the challenges and opportunities in translating complex multi-omics data into meaningful biomarker discoveries. Attendees will learn about state-of-the-art in silico techniques that help decipher the vast amounts of information generated from these studies, enabling them to identify the most promising biomarkers for additional investigation. Do not miss this opportunity to stay at the forefront of oncology drug development.

Register for this webinar to learn how to harness the full potential of multi-omics data and advanced patient models to drive early biomarker discovery.

Speaker

Rajendra Kumari, Crown Bioscience

Rajendra Kumari, PhD, Executive Director, Scientific Operations, Crown Bioscience

Rajendra Kumari leads the focus of cross-disciplinary integrated solutions for drug discovery and development at Crown Bioscience.

She has over 20 years of oncology research experience with a PhD in Molecular Pharmacology. Prior to joining Crown Bioscience, Rajendra held the Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities.

Rajendra also co-founded PRECOS Ltd. in 2010, serving as COO and then following the merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience, working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities.

Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.

Message Presenter

Who Should Attend?

This webinar is ideal for professionals involved in oncology drug development, including:

  • Oncology Researchers/Scientists
  • Bioinformaticians/Data Scientists
  • Preclinical/Clinical Development teams
  • Pharmaceutical/Biotechnology Executives
  • Translational Medicine Researchers

What You Will Learn

Attendees will learn about:

  • How to integrate multi-omics data from diverse oncology models to identify early biomarkers and de-risk drug development
  • Strategies for translating complex in vitro and in vivo data into actionable insights for clinical decision-making
  • Optimal methods for utilizing advanced patient models like organoids and PDX in precision medicine
  • Leveraging in silico expertise to enhance biomarker discovery and inform clinical trial strategies

Xtalks Partner

Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) dedicated to improving human health through partnering with biotech and pharmaceutical companies that drive the discovery and development of oncology drugs. We exclusively offer preclinical tumor organoid services using the well-established Hubrecht Organoid Technology, with over 600 organoid models available spanning 22 cancer indications. In addition, we have developed the world’s largest commercially available PDX collection. Further committed to personalized medicine, our subsidiary, Indivumed Services, maintains an extensive biobank of liquid and tissue human biospecimens. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 12 facilities across the US, Europe, and Asia.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account